Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Stemchymal for PolyQ Spinocerebellar Ataxia
NCT06397274Phase 2Not yet recruiting
- Sponsor
- Steminent Biotherapeutics
- Start
- Jun 2025
- Primary completion
- Jun 2028
- Modality
- Mesenchymal Stem Cells
01
Overview
Phase 2, randomised, double-blind trial in spinocerebellar ataxia type 3 (SCA3) comparing Stemchymal with Placebo (2 arms). Primary endpoint: Scale for the Assessment and Rating of Ataxia at 6 months. Planned start Jun 2025; status: not yet recruiting.
02
Drugs
Stemchymal
03
Conditions
spinocerebellar ataxia type 3 (SCA3)
Beyond the preview
Go deeper on NCT06397274.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06397274.